BlinkLab

Study with Columbia University on Spinocerebellar Ataxias

Partnership aligns with BlinkLab’s strategy to enhance its AI-powered digital platform for sensory phenotyping and promote global adoption.

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI-powered diagnostic tests for neurological disorders, advises it will be participating in a clinical study in patients with spinocerebellar ataxias conducted by Columbia University, New York.


Highlights

  • New study in partnership with Columbia University, New York, to study the effect of aerobic physical exercise on neuroplasticity in adults with spinocerebellar ataxias (“SCA”).
  • Potential to demonstrate that the BlinkLab eyeblink conditioning test can serve as an effective biomarker for neuroplasticity in human SCA patients.
  • Partnership will contribute to global adoption of the BlinkLab platform by world renowned centres and research institutions to study a variety of neurological disorders.
  • Study will continue for up to 18 months and will recruit up to 62 adults with SCA.
  • Collaboration agreement ensures that BlinkLab will have an option to exclusively licence any intellectual property developed as a direct result of the partnership.
Henk-Jan Boele, CEO of BlinkLab commented:

“Since the very first successful test of the BlinkLab platform in the lab at Princeton University, our team’s vision has always been to develop a tool that will someday be considered as a standard of care in the initial diagnosis of neurodevelopmental conditions where children have difficulties in processing sensory information, such as autism and ADHD. However, as a team of scientists we also envisioned the development of a research platform that would facilitate groundbreaking digital sensory phenotyping in neuropsychiatric conditions in a much broader sense. In the past few months we have made significant progress towards this goal as evident from the adoption rate of our technology among top researchers across a broad range of neuropsychiatric clinical disciplines. We know that research adoption will smoothen clinical adoption. Data generated from these studies will further inform our machine learning training and ensure BlinkLab remains the leader in the field of digital sensory phenotyping in humans.”

What is Spinocerebellar Ataxia?

Spinocerebellar ataxias are a group of disorders in which progressive cerebellar degeneration leads to severe disability and even death. An estimated 150,000 Americans are living with these diseases1, and the average annual healthcare cost to the United States is over 1.9 billion dollars2. There are currently no effective treatments or cures for genetic causes of these diseases. Thus, there is a critical need to find treatments that slow disease progression and allow affected individuals to live more functional lives.

Researchers at Columbia University Medical Center demonstrated that aerobic training is a promising treatment for spinocerebellar ataxias, but the mechanism of action is not fully understood. Training may increase leg strength and endurance which allow compensation for balance deficits, but may also cause neuroplastic changes in the brain that are of benefit. In fact, long-term aerobic training in healthy individuals has been shown to create a fertile brain environment by increasing expression of plasticity-related genes and growth factors to support subsequent learning.

Prior work with in-person laboratory assessments has shown that individuals with spinocerebellar ataxia have impaired eyeblink conditioning, poor retention of learning, and difficulty increasing learning capacity across multiple training sessions. There are no published studies in humans examining the impact of exercise training on eyeblink conditioning, but a few animal studies have been conducted. Experimental animals that perform aerobic exercise are able to condition (i.e. associative learning tasks) significantly better than sedentary rats.

Dr. Scott Barbuto, Columbia University, commented on the study:

”The current study will investigate the impact of acute and long-term aerobic training on eyeblink conditioning in individuals with spinocerebellar ataxia. The aim of this study is to demonstrate that aerobic training, but not balance training, causes neuroplastic changes in the cerebellum to enhance motor learning. Eyeblink conditioning has had limited use in clinical studies and is used more often in basic science research. Reasons for limited use include: the high cost of the standard equipment setup needed to test eyeblink conditioning and the need for extensive programming and data management skills to acquire and interpret data. Some studies have been conducted on individuals with spinocerebellar ataxia, but sample sizes are typically very small, ranging from 8-24 participants. With the use of BlinkLab, we will be able to test many individuals with ataxia and determine if differences exist between various types. We will also determine if exercise impacts eyeblink conditioning in individuals with ataxia, a topic that has not been investigated to date.”


Click here for the full ASX Release

This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BB1:AU
BlinkLab Limited

BlinkLab Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
BlinkLab Limited

BlinkLab Limited


Keep reading...Show less
Rocketboots Limited

Appendix 4D & Half Year Report (1H25)

Artificial Intelligence software companyRocketBoots Limited (ASX:ROC) (RocketBoots or the Company) has announced Appendix 4D & Half Year Report (1H25).


Keep reading...Show less
Nanoveu

Binding Share Sale Agreement Executed with EMASS

Nanoveu positioned to accelerate growth in AI-driven edge semiconductor solutions

Nanoveu Limited ("Nanoveu" or the "Company") (ASX: NVU), following on from its announcements on 15 October 2024 and 22 November 2024, is pleased to announce the completion of its binding Share Sale Agreement regarding its 100% acquisition of Embedded A.I. Systems Pte. Ltd. (“EMASS”), a leading System-on-Chip (SoC) semiconductor design company, following shareholder approval and completion of due diligence4. This transaction marks a key strategic moment for Nanoveu and adds cutting edge semiconductor technology to its suite of commercial offerings.

Keep reading...Show less
BlinkLab

North Shore Pediatric Therapy in Chicago Joins BlinkLab’s US Registrational Study

BlinkLab Limited (ASX:BB1) (“BlinkLab”, or the “Company”), an innovative digital healthcare company developing AI-powered smartphone technology to transform the autism and ADHD diagnostic markets, is pleased to announce that North Shore Pediatric Therapy (“NSPT”) is joining our US clinical study. NSPT is the second US-based site to on-board for the 100-patient initial phase of the registrational study. Enrolment from the NSPT-site is expected to commence in the coming weeks.

Keep reading...Show less
Bar chart.

Tech 5: AMD, Alphabet, Amazon and More Report Results as Big Tech Earnings Roll Out

Trade tensions dominated the macroeconomic landscape this week, impacting the tech sector.

US President Donald Trump's confirmation of tariffs against Canada and Mexico resulted in significant market losses on Monday (February 3) before negotiations led to temporary delays in their implementation.

Uncertainties are ongoing, but investors remained resilient, seizing opportunities in the face of volatility as Big Tech earnings reports drove fluctuations in the Nasdaq Composite (INDEXNASDAQ:.IXIC) and S&P 500 (INDEXSP:.INX).

Keep reading...Show less
ChatGPT logo overlayed on human profile.

How to Invest in OpenAI's ChatGPT

OpenAI’s ChatGPT is one of the latest technological breakthroughs in the artificial intelligence space. But what is ChatGPT, and can you invest in OpenAI?

This emerging technology is representative of a niche subsector of the AI industry known as generative AI — systems that can generate text, images or sounds in response to prompts given by users.

Precedence Research expects the global AI market to grow at a compound annual growth rate (CAGR) of 19.1 percent to reach US$3.68 trillion by 2034. Just how much of an impact OpenAI’s ChatGPT will have on this space is hard to predict, but Fortune Business Insights estimates that the total market revenue of generative AI will see a CAGR of 39.6 percent through 2032, increasing from US$67.18 billion last year to US$967.65 billion in 2032.

Keep reading...Show less
BlinkLab Limited

BlinkLab Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×